Picture of ANI Pharmaceuticals logo

ANIP ANI Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+17.34%
3m+18.8%
6m-1.47%
1yr+39.58%
Volume Change (%)
10d/3m+32.27%
Price vs... (%)
52w High-1.3%
50d MA+15.62%
200d MA+22.24%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)15.12
PEG Ratio (f)0.24
EPS Growth (f)167.52%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.39
Price to Tang. Book7.5
Price to Free Cashflow13.32
Price to Sales3.01
EV to EBITDA14.57

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital6.19%
Return on Equity4.15%
Operating Margin9.65%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m206.55208.47216.14316.38486.82535.28575.7619.28%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-33.68n/an/an/an/a+391.08+12.84n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of ANI Pharmaceuticals EPS forecast chart

Profile Summary

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 11th, 2001
Public Since
May 4th, 2000
No. of Shareholders
264
No. of Employees
642
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
21,078,986

ANIP Share Price Performance

Upcoming Events for ANIP

Q1 2024 ANI Pharmaceuticals Inc Earnings Release

ANI Pharmaceuticals Inc Annual Shareholders Meeting

Q2 2024 ANI Pharmaceuticals Inc Earnings Release

Similar to ANIP

Picture of 111 logo

111

us flag iconNASDAQ Global Market

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of Aquestive Therapeutics logo

Aquestive Therapeutics

us flag iconNASDAQ Global Market

Picture of Avadel Pharmaceuticals logo

Avadel Pharmaceuticals

us flag iconNASDAQ Global Market

FAQ